Anthelmintic Chemotypes Targeting TRP Channels to Overcome Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel anthelmintic agents to combat parasitic flatworm infections, as existing drugs like praziquantel have limitations including drug resistance and inadequate treatment options, particularly for neglected tropical diseases.
Innovation Solution
Development of novel chemotypes that act as broad-spectrum transient receptor potential melastatin-praziquantel (TRPMPZQ) channel activators, specifically compounds of Formula (I′), to treat parasitic flatworm infections by activating TRP channels and causing paralysis or inhibiting growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If praziquantel is used to treat parasitic flatworm infections, then existing treatment options are available, but drug resistance develops and treatment effectiveness decreases
Solution Approach 1:
The patent applies parameter changes by developing novel chemotypes with different molecular structures (Formula I compounds) that activate TRP channels through distinct mechanisms compared to praziquantel. This structural parameter change enables the drugs to overcome resistance developed against praziquantel while maintaining the same therapeutic function of inducing worm paralysis through Ca2+ influx.
2Adaptability or versatility
If novel anthelmintic agents are developed, then alternatives to praziquantel are available, but the complexity of drug development increases
Solution Approach 1:
The patent employs universality by designing a series of compounds (Formula I) with variable substituents (R1-R6) that can be systematically modified to create multiple anthelmintic agents with different properties. This modular approach allows diverse drug options to be developed from a common structural framework, managing development complexity through pattern recognition and systematic variation.
3Adaptability or versatility
If TRP channel activators are used to treat parasitic infections, then broad-spectrum activity is achieved, but specificity to parasitic channels must be maintained to avoid off-target effects
Solution Approach 1:
The patent applies local quality by designing TRP channel activators with specific molecular features (substituents R1-R6 in Formula I) that optimize interaction with parasitic TRP channel structures. The compounds are engineered to exploit structural characteristics unique to parasitic flatworm TRP channels, achieving broad-spectrum activity across different parasite species while maintaining specificity that prevents off-target effects on host channels.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel chemotypes effectively activate TRP channels in parasitic flatworms, leading to paralysis and growth inhibition, providing an alternative to praziquantel and addressing drug resistance issues.
Implementation Method 1
PZQ activates a flatworm transient receptor potential (TRP) channel within the melastatin family (TRPMPZQ) to mediate sustained Ca2+ influx and worm paralysis
Implementation Method 2
PZQ activates a flatworm transient receptor potential (TRP) channel within the melastatin family (TRPMPZQ) to mediate sustained Ca2+ influx and worm paralysis
Implementation Method 3
PZQ activates a flatworm transient receptor potential (TRP) channel within the melastatin family (TRPMPZQ) to mediate sustained Ca2+ influx and worm paralysis
Data Source
AI summary
The present disclosure provides novel chemotypes, pharmaceutical compositions thereof, and method of use thereof for treating parasitic infection, including infection caused by parasitic flatworms. The present compounds may be useful as alternatives to praziquantel and may have improved activities against parasitic infections, particularly parasitic flatworm infections.